Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO
Annual Congress 2016
Data from the Phase 1 portion of the ECHO-202 study evaluating epacadostat in combination with
Keytruda® (pembrolizumab) to be highlighted as a poster discussion
Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been
accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual Congress 2016, taking place in
Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat,
Incyte’s selective IDO1 inhibitor, in combination with Keytruda® (pembrolizumab)*, Merck’s anti-PD-1 therapy.
Poster details:
Epacadostat Plus Pembrolizumab in Patients With Advanced Melanoma and Select Solid Tumors: Updated Phase 1 Results From
ECHO-202/KEYNOTE-037 (Abstract #1110PD)
- Monday, 10 October 2016 from 11:00-12:00 CET
Full session details and data presentation listings for ESMO 2016 can be found at http://esmo.org/Conferences/ESMO-2016-Congress/Programme.
About Epacadostat (INCB024360)
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive enzyme that modulates the anti-tumor immune response by
promoting regulatory T cell generation and blocking effector T cell activation, thereby facilitating tumor growth by allowing
cancer cells to avoid immune surveillance. Epacadostat is a first-in-class, highly potent and selective oral inhibitor of the IDO1
enzyme that reverses tumor-associated immune suppression and restores effective anti-tumor immune responses. In single-arm studies,
the combination of epacadostat and immune checkpoint inhibitors has shown proof-of-concept in patients with unresectable or
metastatic melanoma. In these studies, epacadostat combined with the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor
pembrolizumab improved response rates compared with studies of the immune checkpoint inhibitors alone. A Phase 3 study, ECHO-301,
evaluating the combination of epacadostat with the anti-PD-1 antibody pembrolizumab for the first-line treatment of patients with
advanced or metastatic melanoma has recently been initiated. Ongoing Phase 1 and Phase 2 studies are investigating epacadostat in
combination with PD-1 and PD-L1 inhibitors in a variety of other cancer histologies.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements
regarding the presentation of data regarding the Company’s ECHO-202 study, contain predictions, estimates and other forward-looking
statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties
that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or
safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and
uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors
and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the
Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2016. Incyte disclaims any intent or
obligation to update these forward-looking statements.
* KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Incyte Corporation
Media:
Catalina Loveman, +1 302-498-6171
cloveman@incyte.com
or
Investors:
Michael Booth, DPhil, +1 302-498-5914
mbooth@incyte.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160719005754/en/